Justin Renz

Justin has served as our Chief Financial & Operations Officer since 2023. Justin joined Ardelyx in June 2020 as our Chief Financial Officer. Justin brings more than 25 years of experience in the biopharmaceutical industry, with an extensive array of financial and operational experience.

Prior to Ardelyx, Justin served as the president and chief financial officer of Correvio Pharma, a global specialty pharmaceutical company dedicated to the commercialization of cardiovascular and infectious disease products, where he led the sale of the company to ADVANZ PHARMA in May 2020. Prior to Correvio, Justin was executive vice president, chief financial officer, and treasurer of Karyopharm Pharmaceuticals, where he led core business and finance functions and multiple financings. Before Karyopharm, Justin was executive vice president and chief financial officer at Zalicus Inc. (formerly CombinatoRx, Inc.), which he joined in 2006. At Zalicus, Justin oversaw multiple rounds of equity and debt financings, led the company’s asset monetization strategy and was instrumental in the reverse merger and sale of Zalicus to EPIRUS Biopharmaceuticals Inc. in July 2014. Earlier in his career, Justin held numerous positions of increasing responsibility at EMD Serono Inc., ArQule, Inc., Coley Pharmaceutical Group, and Millipore Corporation.

Justin began his career with Arthur Andersen LLP in 1993. He earned a Bachelor of Arts in economics and accounting from the College of the Holy Cross, a Master of Science in taxation from Northeastern University, and a Master of Business Administration from Suffolk University. He is also a certified public accountant in Massachusetts.

“The race always hurts. Expect it to hurt. You don’t train so it doesn’t hurt. You train so you can tolerate it.”

— Eliud Kipchoge